NCT05460481View on ClinicalTrials.gov

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

PHASE2UnknownINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 12, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2024

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Anlotinib Plus Penpulimab

Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.

Trial Locations (1)

410000

RECRUITING

Hunan Cancer hospital, Changsha

Sponsors
All Listed Sponsors
collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Hunan Cancer Hospital

OTHER